3SBio Inc. announced that the first patient has recently been enrolled in the trial of Phase III clinical study of recombinant human thrombopoietin (rhTPO) injection in the treatment of patients with chronic liver disease related thrombocytopenia who are candidates for invasive surgery (project number: TPO106). This is a voluntary announcement made by the Company. The Company cannot guarantee that it is able to successfully develop or eventually launch and/or commercialize such product.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. By order of the Board. 3SBio Inc. Dr. LOU Jing.

Chairman. Shenyang, the PRC. 22 May 2023.

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Directors; and Mr. PU Tianruo, Ms. YANG, Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry and Dr. Zhang Dan as independent non-executive Directors. 3SBio Inc. announces that the first patient has recently be enrolled in the trial of Phase II clinical study of recombinant humanthrombopoietin(rhTPO) injection injection In the field of chronic liver disease, TPIAO is also actively expanding its indications, and exploratory studies on safety, tolerability, pharmacokinetics (PK) and preliminary efficacy have been conducted on patients with chronic liver disease complicated withthrombocytopenia. Thrombocytopenia is a common complication of chronic liver disease, the degree of which is related to the severity of liver disease.

About 78% of patients with liver cirrhosis have varying degrees of thrombocytopenIA. The main cause of thrombocytopania in patients with chronic liver disease is decreased production of thrombocytopin (TPO). Other factors include hypersplenism, increased platelet destruction, and bone marrow suppression by virus.

For patients with chronic liver disease requiring surgery treatment, thrombocytopenia can lead to increased risk of surgery-related bleeding. At present, platelet transfusion is the main treatment to reduce the risk of surgical bleeding. However, its source is scarce and the curative effect is short-lived.

It also carries risks of blood transfusion reaction and potential transfusion infection, limiting its application. Patients with chronic liver disease complicated with thrombocytopenia urgently need more effective and safe alternative treatment methods.